Literature DB >> 7713062

FDG-PET in children and adolescents with partial seizures: role in epilepsy surgery evaluation.

W D Gaillard1, S White, B Malow, R Flamini, S Weinstein, S Sato, C Kufta, S Schiff, O Devinsky, S Fazilat.   

Abstract

We used FDG-PET to measure interictal glucose metabolism in 16 children and adolescents (mean age 14.7 years) and complex partial seizures (CPS) (mean seizure onset age 5.0 years). Video-EEG localized the epileptic foci. Glucose metabolism was determined in 14 paired anatomic areas using a standard template. PET hypometabolism was defined as greater than 15% asymmetry. Nine of the 13 (69%) patients with a unilateral EEG focus had regional hypometabolism ipsilateral to the epileptogenic zone. Three subjects had bilateral EEG foci; all had nonfocal PET. MRI (15 patients) concurred with EEG and PET in two, and was normal in seven of nine with focal hypometabolism. One of seven patients with normal PET had a focal MRI abnormality. FDG-PET results are similar to those found in adults, but are present earlier in the natural history of CPS (9.7 vs 22.2 years duration epilepsy) than previously reported. The presence of FDG-PET hypometabolism may be associated with a poor response to drug treatment. PET can identify metabolic abnormalities associated with epileptic foci in children and adolescents and is useful in directing surgical intervention for the control of refractory complex partial epilepsy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7713062     DOI: 10.1016/0920-1211(94)00065-5

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  8 in total

1.  Objective detection of epileptic foci by 18F-FDG PET in children undergoing epilepsy surgery.

Authors:  Ajay Kumar; Csaba Juhász; Eishi Asano; Sandeep Sood; Otto Muzik; Harry T Chugani
Journal:  J Nucl Med       Date:  2010-11-15       Impact factor: 10.057

2.  Is 11C-flumazenil PET superior to 18FDG PET and 123I-iomazenil SPECT in presurgical evaluation of temporal lobe epilepsy?

Authors:  R M Debets; B Sadzot; J W van Isselt; G J Brekelmans; L C Meiners; A O van Huffelen; G Franck; C W van Veelen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

3.  Three- to five-dimensional biomedical multisensor imaging for the assessment of neurological (dys) function.

Authors:  L M Bidaut; R Pascual-Marqui; J Delavelle; A Naimi; M Seeck; C Michel; D Slosman; O Ratib; D Ruefenacht; T Landis; N de Tribolet; J R Scherrer; F Terrier
Journal:  J Digit Imaging       Date:  1996-11       Impact factor: 4.056

4.  Objective PET study of glucose metabolism asymmetries in children with epilepsy: Implications for normal brain development.

Authors:  Vinod K Pilli; Jeong-Won Jeong; Praneetha Konka; Ajay Kumar; Harry T Chugani; Csaba Juhász
Journal:  Hum Brain Mapp       Date:  2018-08-23       Impact factor: 5.038

5.  Lateralizing ability of single-voxel proton mr spectroscopy in hippocampal sclerosis: comparison with mr imaging and positron emission tomography.

Authors:  S W Park; K H Chang; H D Kim; I C Song; D S Lee; S K Lee; C K Chung; I K Yu; M H Han; Y H Park
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

6.  Assessment of the role of FDG PET in the diagnosis and management of children with refractory epilepsy.

Authors:  Glenn P Ollenberger; Amanda J Byrne; Salvatore U Berlangieri; Christopher C Rowe; Kunthi Pathmaraj; David C Reutens; Samuel F Berkovic; Ingrid E Scheffer; Andrew M Scott
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-03       Impact factor: 9.236

7.  Quantitative brain surface mapping of an electrophysiologic/metabolic mismatch in human neocortical epilepsy.

Authors:  Bálint Alkonyi; Csaba Juhász; Otto Muzik; Eishi Asano; Anita Saporta; Aashit Shah; Harry T Chugani
Journal:  Epilepsy Res       Date:  2009-09-05       Impact factor: 3.045

Review 8.  Antioxidant drug therapy as a neuroprotective countermeasure of nerve agent toxicity.

Authors:  Jennifer N Pearson-Smith; Manisha Patel
Journal:  Neurobiol Dis       Date:  2019-04-25       Impact factor: 5.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.